Colorectal Cancer

Experts highlight the need for tailored care strategies to address fertility, financial strain and survivorship challenges in younger adults with cancer.

An expert explains ostomy bags and how new technologies are improving comfort and quality of life after colorectal cancer surgery.

New data highlight colorectal cancer rates in younger adults, emphasizing the need for earlier screening, symptom awareness and timely diagnosis.

Research shows lifestyle and gut bacteria may drive early-onset colorectal cancer, emphasizing diet and healthy habits to help lower risk.

New NCCN guidelines highlight how structured exercise and molecular profiling significantly reduce recurrence rates.

Experts highlight rising cancer rates in younger adults and the need for tailored support, treatment and survivorship care across the continuum.

COA updates on PBM reform, patient advocacy, and community oncology events to keep patients and advocates informed and empowered.

For me, Colorectal Cancer Awareness Month is about my brother, Jimmy, who died from colorectal cancer at the age of 36.

Survey shows 92% of eligible adults support coverage for colorectal cancer blood tests to improve screening access and adherence.

A colorectal cancer survivor shares what life with an ostomy is really like, offering advice and reassurance for patients adjusting after surgery.

Forget the outdated image of colon cancer as a disease for the elderly. The new, and increasingly common, faces of this disease are pictured here.

Majority of Americans say they don’t have time for colorectal cancer screening, prioritizing household chores instead of their health.

Knowledge gaps and dismissed symptoms may contribute to rising deaths in younger adults.

The U.S. FDA has granted traditional approval to Braftovi with Erbitux and chemo for adults with BRAF V600E metastatic colorectal cancer.

Braftovi plus Erbitux and FOLFIRI improved progression-free survival in untreated BRAF V600E metastatic colorectal cancer in the phase 3 BREAKWATER trial.

I never thought about mantras until my diagnosis with colon cancer at the age of 34.

The U.S. FDA has granted fast track status to pelareorep combination therapy for some KRAS-mutant, microsatellite-stable metastatic colorectal cancers.

The FDA accepted a new drug application for zanzalintinib plus immunotherapy after showing improved survival in some previously treated colorectal cancers.

A phase 2 trial showed onvansertib plus FOLFIRI and Avastin improved response and disease control in first-line RAS-mutated metastatic colorectal cancer.

The FDA approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Braftovi with Erbitux and chemotherapy.

Colorectal Cancer Alliance urges action through Project Cure CRC.

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients with BRAF V600E mCRC.

Study findings show more colorectal cancer risk reduction and safety with the use of a GLP-1RA versus Aspirin.

Physical activity, especially walking, was linked to less fatigue and better quality of life for patients with colorectal cancer, particularly in early survivorship.

Patients with stage 3 colorectal cancer who tested MRD-positive with Signatera after surgery saw a meaningful survival benefit from Celebrex plus chemotherapy.